CagriSema provides ‘substantial’ body weight reductions, research reports

An international type 2 diabetes expert presented the latest findings from the REDEFINE 2 study at the prestigious European Association for the Study of Diabetes (EASD) 2025 meeting.

Professor Melanie Davies, from the University of Leicester, gave delegates a first look at the results, showing that once-weekly CagriSema 2.4 mg/2.4 mg provided clinically meaningful weight reduction in adults with overweight or obesity and type 2 diabetes.

According to her presentation, nearly one out of three people treated with CagriSema 2.4 mg/2.4 mg lost 20 per cent of their body weight compared to 0.2 per cent among those treated with Placebo.

Significantly more participants treated with CagriSema 2.4 mg/2.4 mg achieved HbA1c reduction thresholds, the study has reported.

In addition, the research shows that participants treated with CagriSema 2.4 mg/2.4 mg were more likely to achieve normoglycaemia.